1G·

Investment Thesis: High-Moat Chronic Care Leader with Strong Valuation Upside

$COLO B (+1,44%)

1. Business Model – Simple & Resilient


  • Core focus: Disposable medical products for chronic conditions
  • Key segments: Ostomy, Continence, Voice & Respiratory, Advanced Wound Care
  • Recurring revenues: Chronic patients, high brand loyalty
  • Channels: B2B2C, strong ties with healthcare providers



2. Durable Competitive Moat


  • Market share leadership: 35–40% Ostomy, 40–45% Continence, ~80% Laryngectomy
  • Sustained profitability: 27–32% EBIT margins (5Y avg, above peers)
  • Value creation: ROIC 11.4% vs WACC 4.17%
  • Pricing power: 7–8% organic growth despite reimbursement pressure
  • High switching costs: Reluctance of chronic patients to change products
  • Innovation moat: ~4% of sales in R&D



3. Management Quality


  • Disciplined capital allocation: Atos (€16B), Kerecis (€9B) acquisitions
  • Dividend policy: Target 60–80% payout, temporarily elevated
  • Leverage discipline: Net Debt/EBITDA target 1.5x by 2030
  • Clear roadmap: Impact4 strategy – measurable 5Y growth plan



4. Valuation – Significant Upside


  • Current price: 617 DKK
  • Intrinsic value (base): 959 DKK → +55% upside
  • DCF (2-stage): 1,226 DKK/share
  • Phase 1: 7% CAGR (5Y, in line with guidance)
  • Terminal: 2.5%
  • WACC: 4.17%
  • EPV floor: 334 DKK (downside protection)
  • IV triangulation: 334 (bear) | 959 (base) | 1,472 (bull)
  • Call: BUY – High Confidence



5. Key Strengths


  • Competitive: Market leadership, global footprint (30+ countries), robust pipeline, selective D2C
  • Financial: EBIT margins 27%, ROE 24.7%, FCF yield 3.7%, solid balance sheet (ICR 11x)
  • Strategic: Impact4 growth plan, ROIC >20% target, portfolio focus on high-margin chronic care, deleveraging initiatives



6. Risk Factors


  • Sector: U.S. reimbursement cuts, FDA/EMA regulation, pricing pressure via tenders
  • Company: Premium valuation (PE 34x), FX exposure, integration/execution risks



Mitigation: Diversified product/geography mix, strong innovation moat, proven execution


Conclusion: Attractive entry point in a high-barrier chronic care leader with durable moat, strong financials, and >50% upside potential.


Let me know your thoughts

3
Partecipa alla conversazione